Comparative Pharmacology
Head-to-head clinical analysis: ARTESUNATE versus PRIMAQUINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARTESUNATE versus PRIMAQUINE.
ARTESUNATE vs PRIMAQUINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Artesunate is a water-soluble artemisinin derivative that produces rapid parasite clearance. It is converted in vivo to dihydroartemisinin, which generates free radicals that alkylate and damage parasite proteins, particularly targeting the sarcoplasmic/endoplasmic reticulum calcium ATPase (SERCA) of Plasmodium species.
Antimalarial agent that eliminates exoerythrocytic forms (hypnozoites) of Plasmodium vivax and P. ovale; also active against gametocytes. Mechanism involves generation of reactive oxygen species via redox cycling, disrupting parasite mitochondrial function.
2.4 mg/kg IV at 0, 12, 24, and 48 hours, then daily until oral therapy can be initiated.
15 mg (base) orally once daily for 14 days for radical cure of P. vivax and P. ovale; 30 mg (base) orally once daily for 7 days for terminal prophylaxis.
None Documented
None Documented
Clinical Note
moderatePrimaquine + Norfloxacin
"Primaquine may increase the QTc-prolonging activities of Norfloxacin."
Clinical Note
moderatePrimaquine + Haloperidol
"Primaquine may increase the QTc-prolonging activities of Haloperidol."
Clinical Note
moderatePrimaquine + Ibandronate
"Primaquine may increase the QTc-prolonging activities of Ibandronate."
Clinical Note
moderatePrimaquine + Tenofovir disoproxil
"The metabolism of Tenofovir disoproxil can be decreased when combined with Primaquine."
Terminal elimination half-life of artesunate is approximately 1 hour. The active metabolite dihydroartemisinin has a half-life of 1-2 hours. This short half-life supports rapid parasite clearance in severe malaria.
Terminal elimination half-life of approximately 4-7 hours; in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency, half-life may be prolonged due to accumulation in erythrocytes
Primarily hepatic metabolism; renal excretion of metabolites accounts for <10% as unchanged drug. Biliary/fecal elimination is minimal. ~80% of the dose is recovered in urine as metabolites, mainly dihydroartemisinin.
Primarily renal (60-65% as unchanged drug and metabolites); small amounts in feces (<5%)
Category C
Category D/X
Antimalarial
Antimalarial